Clinical Trials
20 trialsNCT01660984 2026-06-05
Natural History Study of Children and Adults With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Recruiting
NCT04104529 2026-06-04
BCB RIV
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Recruiting
NCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01005654 2026-06-01
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
National Institutes of Health Clinical Center (CC)
Recruiting
NCT03914300 2026-06-01
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04284774 2026-05-27
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04759911 2026-05-20
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00001160 2026-05-12
Studies on Tumors of the Thyroid
National Institutes of Health Clinical Center (CC)
Recruiting
NCT01398085 2026-05-07
IoN
University College, London
Phase 2/3 Active not recruiting
NCT06730321 2026-05-07
Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)
Shanghai 6th People's Hospital
Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT07536412 2026-04-17
Decision Aid Efficacy in Low Risk Thyroid Cancer
University of Maryland, Baltimore
Phase NA Not yet recruiting
NCT01709292 2026-04-16
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT07485569 2026-04-15
REPOTHYROID-II
Radboud University Medical Center
Phase 1 Not yet recruiting
NCT02152995 2026-04-13
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04948437 2026-04-13
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
National Taiwan University Hospital
Active not recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting